Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

OBJECTIVE: To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: This randomized, double-blind trial includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieber, Thomas R., Aronson, Ronnie, Hövelmann, Ulrike, Willard, Julie, Plum-Mörschel, Leona, Knudsen, Kim M., Bandak, Benedikte, Tehranchi, Ramin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247529/
https://www.ncbi.nlm.nih.gov/pubmed/35239971
http://dx.doi.org/10.2337/dc20-2995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247529/
https://www.ncbi.nlm.nih.gov/pubmed/35239971
http://dx.doi.org/10.2337/dc20-2995

Ejemplares similares